[18F]-Fluorodeoxyglucose Positron Emission Tomography in Lung Tumour Assessment, Research into Characteristics - PLuTARCh

niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 54 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•Adult patients (age 18 years and over) with:
•-Newly diagnosed or suspected NSCLC stage IB, IIB or limited stage III (T3N1) (at least 30mm in smallest diameter);
•-Primary surgical resection (wedge excision, segmentectomy, lobectomy or pneumonectomy).

•- Neoadjuvant treatment prior to surgery;
•- No staging CT or FDG-PET available;
•- Contra-indication for surgery:
•o Based on (biological) age, cardiovascular risk factors, expected remaining lung function, performance status or other co-morbidity as decided by a multidisciplinary team including medical oncologists, thorax surgeons, pulmonologists, radiation oncologists, pathologists, radiologists and nuclear medicine physicians.
•- Contra-indication for dynamic FDG-PET:
•o Diabetes mellitus;
•o Pregnancy;
•o Breast-feeding;
•o Severe claustrophobia.
•o Post-obstruction pneumonia (false-positive FDG-PET)
•- Interval between staging CT/FDG-PET, dynamic FDG-PET and surgery more than 28 days;
•- Histology proven non-NSCLC or high suspicion for tumour of other origin (e.g. metastasis of colorectal, breast or pharyngeal origin);
•- Inability to give informed consent.

发起方

niversitair Medisch Centrum Sint Radboud